Overview

• Lantheus Q3 2025 revenue of $384 mln beats analyst expectations

• Adjusted EPS for Q3 2025 beats analyst estimates

• Company repurchased $100 mln of shares in Q3 2025

Outlook

• Company sees FY 2025 revenue between $1.49 bln and $1.51 bln

• Company expects FY 2025 adjusted EPS of $5.50 to $5.65

• Company does not provide GAAP EPS guidance due to uncertainties

Result Drivers

• PYLARIFY SALES DECLINE - Sales of PYLARIFY decreased by 7.4%, impacting overall revenue growth

• DEFINITY SALES INCREASE - Sales of DEFINITY increased by 6.3%, contributing positively to revenue

• LIFE MOLECULAR ACQUISITION - Acquisition of Life Molecular Imaging expected to enhance growth and portfolio

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Lantheus Holdings Inc is $80.00, about 28.5% above its November 5 closing price of $57.23

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nGNX9ykc6T

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)